Preview

Артериальная гипертензия

Расширенный поиск

Нужно ли пациенту с артериальной гипертонией снижать ЧСС?

https://doi.org/10.18705/1607-419X-2008-14-2-125-130

Полный текст:

Об авторе

В. Маколкин
Московская медицинская академия им. И.М.Сеченова
Россия


Список литературы

1. Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика, 2004; 3(3),ч.1,с.10-14.

2.

3. Levine H.J. Heart rate and life expectancy. J Amer Coll Card 1997;30:1104.

4.

5. Spector W.S. Handbook of Biologocal Data, WB Saunders, Philadelphia,1956, p41.

6.

7. White P.D., Jenkins J.L., Benedict F.G. The electrocardiogram of the elephant. Am Heart J 1938 16:744.

8.

9. Boraso A. Why is reduced heart rate beneficial. Dialogues in Cardiovascular Medicine 2001; 6:19-24.

10.

11. Schmidt-Nielsen K. Animal Phisiology: Adaptation and Environment. New York: Cambridge University Press, 1975, h 133.

12.

13. Beere P., Glagov S., Zarins C. Retarding effect of lowering heart rate on coronary atherosclerosis. Sciente 1984; 226:180-2.

14.

15. Perski A., Hamsted A., Lindvall K., Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction parients. Am Heart J 1988;116:1369-73.

16.

17. Castelli W.P., Levy D., Wilson P.W.F., Kannel W. Sudden death: The view from Framingham. In Kostis JB, Sanders M (eds). The Prevention of Sudden Death. E Wiley-Liss, New York, 1990, pp 1-8.

18.

19. Pepine C.J., Handberg E., Cooper-De-Hoff R. et al. A Calcium Antagonist vs Non-Calcium Antagonist HypertensionTreatment Strategy for Patients With Coronary Artery Disease.The International Verapamil-Trandolapril Study (INVEST):A Randomized Controlled Trial. JAMA, December 3, 2003-Vol290, № 21:2805-2816.

20.

21. Novo S., Alaimo G., Abrignani M.G., Longo B., Muratore G., Strano A. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Journal of Cardiovascular Pharmacology 1989; 13 (Suppl. 4): S38-S41.

22.

23. Safar M., Benetos A., Juvin Ph. et al. Multicentre trial of the antihypertensive efficacy and safety of Verapamil CP. Act. med. Int. - l'Hypertension 1990; 2: 3-7."

24.

25. Holzgreve H., Distler, Michaelis J., Philipp Th., Wellek S. Verapamil versus hydrochlordthiazide in the treatment of hypertension: results of long term double blind comparrati ve trial. Br. Med. J. 1989; 299: 881-886.

26.

27. Stalmach W.J., Rush D.R., Brucker P.C., Holverson H., Huffmann B.L., Kane W.J., Ryan M.F. Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of mild-to-moderate hypertension. J. Amer. Fam. Pract. 1989;2:172-190.

28.

29. Libretti A. Catalono Mon behalf of the SLIP study gropup. Lipid profile during antihypertensive treatment - the SLIP study. Drugs 1993; 46 (Suppl. 2):16-23.

30.

31. Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamilor chlorthalidone on carotid intima-media thickness. J. Hypertens.1997;15:1337-1344.

32.

33. Zanchetti A., Magnani B., Dal Plau С. et al. Clinical results of the verapamil in hypertension and atherosclerosis study (VHAS). J. Hypertens. 1998; 16:1667-1676.

34.

35. Lefrandt J.D., van Roon A.M., van Gessel et al. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertension 1999, 17 (Suppl.3).

36.

37. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; March 21.

38.

39. Grossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80:1453-1458.

40.

41. Silber S., Vogler A., Theisen K. Equal anti-ischemic properties of isosorbide dinitrate plus propranolol - a randomised, double-blind and crossover study. Z. Kardiol., Suppl.3 (1986), 100-105.

42.

43. Pallone N.M. Effect of Calcium Antagonists in the Treatment of Silent Ischemic Heart Disease. Curr. Ther. Res., 45 (1989), 339-346.

44.

45. Danish S.G. on Vin M.I. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990 Oct;66:779-85.

46.

47. Rengo F., Carbon P., Pathor M. et al. A conrolled trial in patients after myocardial infarction: results of the Calcium antagonist Reinfarction Italian Studv. Am. J. Cardiol. 1996; 77: 365-369.

48.

49. Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. 1997; 15:1337-1344.

50.

51. Forslund L., Bjorkander I., Ericksson S. et al. Effect of metoprolol or verapamil treatment on results from exercise testingand long-term ECG recording in stable angina pectoris, Short-term results from the APSIS study. Eur Heart J 1995; 16 AbstractSuppl:422.

52.

53. Heidland U.E., Strauer B.E. Left ventricular vuscle mass and elevated heart rate are associated with coronary plaque di C Puption.Circulation, 2001;104:1477-1482.

54.


Для цитирования:


Маколкин В. Нужно ли пациенту с артериальной гипертонией снижать ЧСС? . Артериальная гипертензия. 2008;14(2):125-130. https://doi.org/10.18705/1607-419X-2008-14-2-125-130

For citation:


Makolkin B. Is it necessary to slow the heart rate in a hypertensive patient? . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(2):125-130. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-2-125-130

Просмотров: 132


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)